Indications
Osteosarcoma: Neoadjuvant and adjuvant chemotherapy are standard components of treatment.
Ewing Sarcoma: Highly chemosensitive; systemic therapy is essential for all patients.
Chondrosarcoma: Generally resistant to conventional chemotherapy; only the dedifferentiated and mesenchymal subtypes may respond.
Other rare tumors (e.g., MFH/UPS, Angiosarcoma): Chemotherapy considered in high-grade or metastatic cases.
Chemotherapy Timing
Type Purpose Typical Use Neoadjuvant Shrink tumor, facilitate limb-salvage surgery, evaluate histologic response Osteosarcoma, Ewing Sarcoma Adjuvant Eliminate residual micrometastatic disease Osteosarcoma Palliative Control symptoms or progression in unresectable/metastatic disease All high-grade sarcomas
Evaluation of Response
Histologic response is assessed by percentage of tumor necrosis in resected specimens:
90% necrosis → good responder<90% necrosis → poor responderImaging: MRI and PET-CT can aid in preoperative assessment but are less reliable than pathology.
Prognostic impact: Histologic response remains one of the strongest predictors of overall survival.
Toxicities and Supportive Care
Acute toxicities: Myelosuppression, mucositis, nausea/vomiting, nephrotoxicity (cisplatin), and cardiotoxicity (doxorubicin).
Long-term complications: Ototoxicity, infertility, secondary malignancies, and renal or cardiac dysfunction.
Supportive strategies:Adequate hydration and mesna for ifosfamide/cyclophosphamide
Dexrazoxane for anthracycline cardioprotection
Growth factor support (G-CSF) to reduce neutropenia
Emerging Therapies
Targeted therapy: IGF-1R inhibitors, mTOR inhibitors, and VEGF-targeted agents show limited but growing promise.
Immunotherapy: Research into checkpoint inhibitors and cell-based therapies (e.g., CAR-T) is ongoing, particularly in relapsed Ewing sarcoma.
Chemo-sensitivity modulation: Nanocarrier drug delivery and combination regimens are under investigation to improve efficacy while minimizing toxicity.
Common Regimens
Tumor Type | Standard Regimen | Key Agents |
Osteosarcoma
| MAP protocol | Methotrexate, Doxorubicin, Cisplatin ± Ifosfamide |
Ewing Sarcoma
| VDC/IE alternating protocol | Vincristine, Doxorubicin, Cyclophosphamide / Ifosfamide, Etoposide |
Mesenchymal Chondrosarcoma
| Ewing-based regimens | VDC/IE or VIDE |
Recurrent Disease
| Salvage chemotherapy | Gemcitabine + Docetaxel, Ifosfamide + Etoposide, or High-dose Ifosfamide |
Key Points
Chemotherapy is mandatory for osteosarcoma and Ewing sarcoma, but ineffective for most low-grade chondrosarcomas.
Histologic necrosis after neoadjuvant therapy remains a critical prognostic factor.
Ongoing trials aim to optimize drug combinations and identify predictive biomarkers for response.
References
Bielack SS et al. Osteosarcoma: ESMO Clinical Practice Guidelines. Ann Oncol. 2022;33(12):1344–1356.
Ladenstein R et al. Ewing Sarcoma: Current Management and Future Directions. J Clin Oncol. 2021;39(26):3039–3053.
Palmerini E et al. Chemotherapy in Chondrosarcoma: When and Why? Eur J Cancer. 2020;140:74–83.
Ferrari S et al. MAP and Beyond: New Horizons in Osteosarcoma Chemotherapy. Cancer Treat Rev. 2023;114:102516.